• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, April 24 Lupin Ltd’s subsidiary in Japan, Kyowa Pharmaceutical Industry Co Ltd, has received approvals for 10 generic drugs from Japan’s Ministry of Health & Labour Welfare. The company expects to these products in Japan in July 2008.

Kyowa’s expanded product basket will now include ten more products including: Amlodipine (a cardio-vascular (CV) medicine), Risperidone (a brand-extension, central nervous system –CNS - medicine), Cabergoline, Milnacipran and Tandospirone also CNS medicines, Meloxicam (a non-steroid anti-inflammatory drug), Fluticasone (line extension for pediatrics; anti-asthma), Quazepam (line extension; CNS), Ethyl Icosapentate and Maprotiline (line extension; CNS), a Lupin note said.

The combined market size of these molecules in Japan is about $2.65 billion as per IMS 2007. Lupin had acquired Kyowa in October 2007 and at present holds over 90 per cent in the Japanese company.

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Lupin gets approval for 10 generic drugs in Japan

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line